Press Releases

Press Releases

Media Contact:
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
wolffe@wheelhouselsa.com

Date Title and Summary Additional Format
November 9, 2020 Nurix Therapeutics to Present at Upcoming Investor Conferences
SAN FRANCISCO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.  (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will be presenting at the following healthcare investor conferences: Stifel 2020 Virtual Healthcare
November 4, 2020 Nurix Therapeutics to Present Preclinical Data at Upcoming 5th Medicinal Chemistry & Protein Degradation Summit and 62nd ASH Annual Meeting and Exposition
SAN FRANCISCO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.  (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will present data on its novel targeted protein degradation platform at the upcoming 5 th Medicinal Chemistry
October 26, 2020 Nurix Therapeutics Announces Appointment of Robert Tjian as Chairman of Scientific Advisory Board and His Resignation from the Board of Directors
SAN FRANCISCO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), today announced that, based on his desire to lead Nurix’s Scientific Advisory Board, Robert Tjian, Ph.D. has resigned from the Company’s Board of Directors effective November 1, 2020. Dr.
October 14, 2020 Nurix Therapeutics Reports Third Quarter Fiscal 2020 Financial Results and Provides a Corporate Update
Completed recent IPO raising approximately $238 .5 million in gross proceeds On track for multiple IND filings SAN FRANCISCO , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics Inc.  (Nasdaq: NRIX), a biotechnology company developing targeted protein modulation drugs, today reported financial
October 6, 2020 Nurix Therapeutics to Present at 3rd Annual Targeted Protein Degradation Summit
SAN FRANCISCO , Oct. 06, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. , (NASDAQ: NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presenting at the 3 rd Targeted Protein Degradation (TPD) Summit held virtually.
July 23, 2020 Nurix Therapeutics Announces Pricing of $209 Million Initial Public Offering
SAN FRANCISCO , July 23, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. ( Nurix ), a company developing targeted protein modulation drugs, today announced the pricing of its initial public offering of 11,000,000 shares of its common stock at a price to the public of $19.00 per share.
July 13, 2020 Nurix Therapeutics Announces Addition of Dr. Jason Kantor to its Management Team
SAN FRANCISCO, July 13, 2020 –  Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the appointment of Dr. Jason Kantor as senior vice president, finance and investment strategy. In this role, Dr. Kantor will be responsible for communicating the vision
June 25, 2020 Nurix Therapeutics Announces Formation of DeCART Therapeutics to Advance New CAR T Therapies Using Targeted Protein Modulation
SAN FRANCISCO, June 25, 2020 –  Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the formation of a new adoptive cell therapy company, DeCART Therapeutics, which has been initially formed as a wholly owned subsidiary of Nurix.
March 12, 2020 Nurix Therapeutics Closes $120 Million Financing to Advance Targeted Protein Modulation Drug Pipeline
SAN FRANCISCO, March 12, 2020 – Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced it has closed an oversubscribed $120 million financing. The round was led by Foresite Capital with participation from Bain Capital Life Sciences, Boxer Capital
February 27, 2020 Nurix Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference
SAN FRANCISCO, February 27, 2020 – Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced that CEO Arthur Sands will present at the Cowen & Co. 40th Annual Health Care Conference on Wednesday, March 4, 2020, 3:30 PM ET in Boston, MA.
Displaying 1 - 10 of 12